Velos has released a new clinical research analytics platform in which the source information is reorganized and reclassified to make it “considerably more useful for clinical research,” says CEO.
Synteract has acquired the dermatology CRO Cu-Tech, opening a fifth center of development as part of its strategy to develop “highly-expert therapeutic areas of focus,” says CCO.
The need to improve visibility, enable faster study execution, and improve study quality, is driving the industry to unify its "broken" clinical trial operating environments, according to a report.
Gemphire Therapeutics tapped the Canton, MI-based contract research organization (CRO) MMS Holdings to help support a Phase IIb clinical trial of its first-in-class drug candidate, Gemcabene.
Cross-industry discussion is expanding from early discovery to post-licensing challenges – as the nexus of innovation and policy improvements is rapidly changing, says DIA executive.
BASi and Seventh Wave Laboratories are joining operations via an asset purchase agreement, through which BASi will lease the CRO's facility in Maryland Heights, MO.
Japan-based ONO Pharmaceutical will use CluePoints’ centralized statistical monitoring platform to lead its RBM strategy over the next four years following a successful pilot study in 2017.
BioIVT adds transporter assay products and services to its ADME-Toxicology portfolio with the acquisition of Optivia Biotechnology – a deal which aligns with the company’s efforts to support drug safety and efficacy, says VP.
GlaxoSmithKline has selected TrialScope to facilitate clinical trial disclosure and transparency – as the benefits of patient centricity are paramount, and the risks of poor compliance magnified, says VP.
CRO Pivotal is collaborating with the non-profit cancer research association APRO to advance investigator-sponsored trials in bladder and prostate cancers.
UDG Healthcare has acquired two healthcare-focused firms, expanding its global footprint and service offerings – including those in health economics and outcomes research – in a deal worth up to $82.4m.
